Last updated: February 15, 2026
Overview of NDC 00904-6337
NDC 00904-6337 corresponds to Monjuvi (tafasitamab), a monoclonal antibody approved by the FDA in August 2020 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are ineligible for autologous stem cell transplant.
Market Landscape
1. Disease Market Size
- DLBCL accounts for 30-40% of non-Hodgkin lymphoma cases worldwide.
- US incidence: Approximately 26,000 new cases annually.
- Prevalence of relapsed/refractory DLBCL remains roughly 50% in initial treatment phases.
- Market opportunity in the US estimated at $2 billion, with global prospects reaching up to $3-4 billion.
2. Competitive Environment
- Key competitors:
- Rituximab-based regimens (R-CHOP).
- Other monoclonal antibodies (e.g., Polivy/polatuzumab).
- CAR-T therapies (e.g., Tecartus, Yescarta).
- Monjuvi, as a targeted therapy with a novel mechanism, positions itself toward a niche with limited CAR-T eligibility.
3. Regulatory and reimbursement stance
- FDA approval in August 2020.
- CMS and private insurers generally cover Monjuvi, though with reimbursement hurdles common to antibody therapies.
- Pricing considerations hinge on comparable treatments' costs, efficacy, and safety profiles.
Market Penetration Trends
- Early adoption by hematologists and oncologists has primarily concentrated in academic centers.
- Monjuvi's use increases when combined with lenalidomide.
- The therapy's uptake lags behind CAR-T due to perceived efficacy and convenience differentials.
- Sales trajectory in 2021 was approximately $200 million worldwide, with growth expected to reach $400 million by 2023, based on pipeline and market expansion.
Pricing Analysis
1. Current Price (April 2023)
- List price per 12 mg vial approximately $4,500.
- Typical treatment involves 12 doses over six cycles; total cost circa $54,000 per patient.
- Pricing varies due to negotiated discounts, rebates, and payer contracts.
2. Cost Comparison
| Therapy |
Approximate Cost per Treatment Course |
Notes |
| Monjuvi (tafasitamab) |
$45,000–$55,000 |
Per treatment course; excludes administration and supportive care |
| Polivy (polatuzumab) |
~$16,000 |
Given in combination; different indication |
| CAR-T (e.g., Yescarta) |
$373,000 |
Higher upfront cost, more invasive |
3. Price Trends and Projections
- Current pricing aligns with other monoclonal antibody therapies.
- No significant reductions anticipated in the short term amid high unmet need.
- Potential for price adjustments depending on biosimilar developments and negotiations.
4. Future Price Dynamics
- Uptake growth could lead to economies of scale, possibly lowering real-world costs.
- Payer pressure may incentivize price reductions as biosimilars or biosimilar-like offerings emerge.
- Potential hydroxychloroquine-level price reductions unlikely; monoclonal antibody pricing has historically remained high due to production costs.
Market Expansion Factors
- Linchpin for growth: expanding indications, combination therapies.
- The pipeline includes trials for additional lymphoma subtypes and other hematologic malignancies.
- Regulatory extensions into off-label uses may elevate demand.
Key Revenue Drivers
- Lymphoma patient population size.
- Treatment guidelines incorporating Monjuvi.
- Insurance reimbursement policies.
- Competition from CAR-T therapies and other biologics.
Risks and Barriers
- Competition from CAR-T therapies may limit incremental growth.
- Reimbursement restrictions may hinder adoption.
- Off-label use limitations and clinical trial outcomes can influence market share.
Summary of Price Projections (2025-2030)
- 2023: Price stabilizes around $4,500 per vial; total course ~$54,000.
- 2025: Slight price adjustments (~+2%) due to inflation and market factors.
- 2030: Possible stabilization or modest decrease (~10%) if biosimilar entrants or generic biologics emerge.
Conclusion
Monjuvi maintains a high-price position typical of monoclonal antibody therapies, with moderate growth expectations driven by expanding indications and clinical data. Market size is constrained by the number of eligible patients but benefits from competition and pipeline expansion. Short-term price reductions are unlikely absent biosimilar competition, but long-term dynamics could pressure pricing downward.
Key Takeaways
- NDC 00904-6337 (Monjuvi) targets relapsed/refractory DLBCL with a global market forecast of $3-4 billion.
- US sales reached approximately $200 million in 2021, with growth prospects to $400 million by 2023.
- Current list price per treatment course remains around $54,000; prices are unlikely to decrease significantly before 2030.
- Competition from CAR-T therapies and pipeline expansion will influence future market share and pricing.
- Payer policies and clinical adoption rates remain critical to sales growth.
FAQs
-
What is the primary indication for Monjuvi?
Relapsed or refractory diffuse large B-cell lymphoma in adults ineligible for stem cell transplant.
-
What are the main competitors to Monjuvi?
CAR-T therapies like Yescarta and Tecartus, and other monoclonal antibodies like Polivy.
-
How is the pricing of Monjuvi comparable to similar biologics?
It aligns with other monoclonal antibody therapies, typically ranging from $4,000 to $4,500 per vial.
-
What factors could influence Monjuvi’s market growth?
Pipeline expansion, additional approved indications, reimbursement policies, and competition.
-
Is biosimilar entry expected?
Potential biosimilar development could occur post-patent expiry (expected around 2028-2030), potentially reducing prices.
Citations
[1] FDA Approved Drugs Database. "Monjuvi (tafasitamab) approval details," 2020.
[2] IQVIA. "US Oncology Market Trends," 2022.
[3] Evaluate Pharma. "Biologic Market Projections," 2023.
[4] Centers for Medicare & Medicaid Services. "Reimbursement Policies for Biologics," 2022.
[5] Company financials and press releases, MorphoSys (main manufacturer).
